ENVB — Enveric Biosciences Balance Sheet
0.000.00%
- $4.85m
- -$1.50m
- 18
- 41
- 20
- 15
Annual balance sheet for Enveric Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K/A | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Cash and Short Term Investments | 0.431 | 1.58 | 17.4 | 17.7 | 2.29 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 6.38 | — | — | — | — |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 7.6 | 2.28 | 17.7 | 18.4 | 3.58 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.369 | — | 0.471 | 0.741 | 0.507 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 25.3 | 4.1 | 26.7 | 19.6 | 4.3 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 14.5 | 0.681 | 2.08 | 4 | 2.34 |
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 14.7 | 0.681 | 4.41 | 4.88 | 2.34 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 10.6 | 3.42 | 22.3 | 14.7 | 1.96 |
Total Liabilities & Shareholders' Equity | 25.3 | 4.1 | 26.7 | 19.6 | 4.3 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |